Evercore ISI analyst Liisa Bayko raised the firm’s price target on Alnylam to $260 from $210 and keeps an Outperform rating on the shares after the company’s HELIOS-B data “beat wavering expectations.” The firm is moving its view of the odds of success for vutrisiran in ATTR-CM patients to 80% from 70% and notes that its “fully loaded” target assuming U.S. approval in Q3 of 2025 would be $300 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam (NASDAQ:ALNY) Soars on Positive Topline Results for Vutrisiran
- Alnylam reports results from its HELIOS-B Phase 3 study of vutrisiran
- Ionis Pharmaceuticals upgraded to Market Perform from Underperform at Bernstein
- Citi opens ‘positive catalyst watch’ on Alnylam in data readout
- Alnylam price target raised to $400 from $395 at H.C. Wainwright
Questions or Comments about the article? Write to editor@tipranks.com